SPDR Gold Trust vs Eli Lilly And Co — how do they compare? SPDR Gold Trust trades at $365.52, while Eli Lilly And Co trades at $1,173.57 (market cap $1.03T). The key difference: Eli Lilly And Co pays a 0.6% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals.
| GLD | LLY | |
|---|---|---|
52-Week High | $495.90 | $1.24K |
52-Week Low | $300.96 | $625.65 |
Market Cap | — | $1.03T |
Sector | — | Health |
Enterprise Value | — | $1.07T |
Dividend Yield | — | 0.6% |
Signals from Pluang's Aura AI — not financial advice
GLD (SPDR Gold Shares ETF) trades at $365.75, down 1.72% amid bearish technical signals with 14 sell indicators. The ETF tracks physical gold prices, currently facing pressure from stabilizing dollar and rate-hike expectations. Recent economic data shows mixed signals with cooling inflation but strong labor market data weighing on gold prices. The fund provides direct exposure to gold bullion with lower volatility compared to mining stocks.
Gold's near-term outlook faces headwinds from potential Fed rate policy and dollar strength, though geopolitical tensions and central bank accumulation provide support. The technical picture suggests consolidation near key support levels with bearish momentum indicators. Investors should monitor Fed policy signals and inflation data for directional catalysts.
Eli Lilly (LLY) trades at $1,176.75, up 1.95% on the day, with strong fundamentals including a 31.66% net margin and consistent earnings beats. The stock shows a bearish technical signal near resistance at $1,177, while recent news highlights the $2.8 billion acquisition of AtaiBeckley to expand its mental health pipeline. Operating cash flow surged to $16.81 billion in 2025, supporting growth initiatives in obesity and Alzheimer's treatments.
Outlook remains positive with a $1.38K analyst price target and 73% buy ratings, but risks include competitive pressure in obesity drugs and high valuation multiples. Revenue growth of 65% in 2025 underscores momentum, though debt levels and acquisition integration pose challenges for sustained outperformance.
Trailing returns across standard periods
Latest headlines on both assets
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →